Imaging activated T cells predicts response to cancer vaccines.

J Clin Invest 2018 06 14;128(6):2569-2580. Epub 2018 May 14.

Department of Radiology.

In situ cancer vaccines are under active clinical investigation, given their reported ability to eradicate both local and disseminated malignancies. Intratumoral vaccine administration is thought to activate a T cell-mediated immune response, which begins in the treated tumor and cascades systemically. In this study, we describe a PET tracer (64Cu-DOTA-AbOX40) that enabled noninvasive and longitudinal imaging of OX40, a cell-surface marker of T cell activation. We report the spatiotemporal dynamics of T cell activation following in situ vaccination with CpG oligodeoxynucleotide in a dual tumor-bearing mouse model. We demonstrate that OX40 imaging was able to predict tumor responses on day 9 after treatment on the basis of tumor tracer uptake on day 2, with greater accuracy than both anatomical and blood-based measurements. These studies provide key insights into global T cell activation following local CpG treatment and indicate that 64Cu-DOTA-AbOX40 is a promising candidate for monitoring clinical cancer immunotherapy strategies.

Download full-text PDF

Source
http://dx.doi.org/10.1172/JCI98509DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5983309PMC
June 2018

Publication Analysis

Top Keywords

cell activation
12
cancer vaccines
8
describe pet
4
day treatment
4
study describe
4
treatment basis
4
responses day
4
pet tracer
4
64cu-dota-abox40 enabled
4
predict tumor
4
tracer 64cu-dota-abox40
4
tumor responses
4
systemically study
4
basis tumor
4
tracer uptake
4
treated tumor
4
uptake day
4
response treated
4
tumor cascades
4
tumor tracer
4

Similar Publications